
Profound Medical Corp. Financial Statements 2025-2011 | PROF
Annual Financial Statements Profound Medical Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
166 M | 185 M | 173 M | 183 M | 230 M | 228 M | 121 M | 88.1 M | - | - | - | - | - | - | - |
Shares |
30.2 M | 24.8 M | 21.2 M | 20.8 M | 20.5 M | 11.1 M | 11.1 M | 10 M | - | - | - | - | - | - | - |
Historical Prices |
5.49 | 7.45 | 8.18 | 8.78 | 11.2 | 20.6 | 10.9 | - | - | - | - | - | - | - | - |
Net Income |
-42.6 M | -27.8 M | -28.3 M | -28.7 M | -30.7 M | -21.6 M | -20.2 M | -20.8 M | -18.8 M | -12.1 M | -11.8 M | -8.2 M | - | - | - |
Revenue |
16.1 M | 10.7 M | 7.2 M | 6.68 M | 6.87 M | 7.3 M | 4.17 M | 2.6 M | 4.9 M | - | - | - | - | - | - |
Cost of Revenue |
4.7 M | 3.64 M | 2.89 M | 3.66 M | 3.92 M | 3.83 M | 1.78 M | - | - | - | - | - | - | - | - |
Gross Profit |
11.4 M | 7.04 M | 4.31 M | 3.02 M | 2.95 M | 3.47 M | - | - | 1.87 M | - | - | - | - | - | - |
Operating Income |
-41.3 M | -33.1 M | -28.7 M | -32.1 M | -30.3 M | -18.9 M | -14.9 M | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | 146 K | 290 K | 448 K | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-40.9 M | -32.4 M | -27.9 M | -32.1 M | -30.3 M | -18.9 M | -14.9 M | - | -17.2 M | -11.4 M | -9.39 M | -6.18 M | - | - | - |
Operating Expenses |
52.6 M | 40.1 M | 33 M | 35.1 M | 33.2 M | 22.3 M | 17.3 M | 21 M | 19.5 M | - | - | - | - | - | - |
General and Administrative Expenses |
32.1 M | 23.1 M | 9.17 M | 9.46 M | 10.3 M | 7.56 M | 7.68 M | 6.66 M | 5.94 M | 4.2 M | 4.39 M | 1.95 M | - | - | - |
All numbers in USD currency
Quarterly Income Statement Profound Medical Corp.
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2023-Q4 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
36.4 M | 36.3 M | 30.1 M | 30.1 M | 30 M | 21.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-9.54 M | -7.05 M | -7.98 M | -15.7 M | -10.7 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
2.48 M | 5.34 M | 5.29 M | 2.21 M | 2.62 M | 7.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
536 K | 1.5 M | 1.36 M | 593 K | 768 K | 2.82 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
1.95 M | 3.83 M | 3.93 M | 1.62 M | 1.85 M | 4.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-11.1 M | -8.02 M | -8.91 M | -13.8 M | -11.2 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | 146 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-10.9 M | -7.93 M | -8.82 M | -13.7 M | -11 M | -28.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
13 M | 11.9 M | 12.8 M | 15.4 M | 13 M | 33 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
7.36 M | 6.59 M | 7.43 M | 9.33 M | 8.21 M | 9.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Main types of financial statements Profound Medical Corp. PROFFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Profound Medical Corp. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Abbott Laboratories
ABT
|
$ 105.33 | 0.03 % | $ 183 B | ||
|
Inspire Medical Systems
INSP
|
$ 62.37 | 0.06 % | $ 1.83 B | ||
|
IRIDEX Corporation
IRIX
|
$ 0.69 | 1.21 % | $ 11.7 M | ||
|
IRadimed Corporation
IRMD
|
$ 84.12 | 0.84 % | $ 1.07 B | ||
|
LENSAR
LNSR
|
$ 8.54 | 1.11 % | $ 102 M | ||
|
Pulmonx Corporation
LUNG
|
$ 2.16 | 1.77 % | $ 87.9 M | ||
|
Medtronic PLC
MDT
|
$ 91.79 | 1.15 % | $ 118 B | ||
|
MiMedx Group
MDXG
|
$ 4.53 | 3.16 % | $ 670 M | ||
|
Axonics Modulation Technologies
AXNX
|
- | - | $ 3.31 B | ||
|
Myomo
MYO
|
$ 1.35 | 2.86 % | $ 56.5 M | ||
|
Nano-X Imaging Ltd.
NNOX
|
$ 0.86 | 3.64 % | $ 55.7 M | ||
|
InspireMD
NSPR
|
$ 0.83 | 1.09 % | $ 53.4 M | ||
|
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | ||
|
Conformis
CFMS
|
- | - | $ 16.4 M | ||
|
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | ||
|
Eargo
EAR
|
- | - | $ 10.2 M | ||
|
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | ||
|
Inari Medical
NARI
|
- | - | $ 4.23 B | ||
|
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | ||
|
NuVasive
NUVA
|
- | - | $ 2.07 B | ||
|
Neovasc
NVCN
|
- | - | $ 111 M | ||
|
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | ||
|
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | ||
|
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | ||
|
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | ||
|
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | ||
|
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | ||
|
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | ||
|
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | ||
|
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | ||
|
Orthofix Medical
OFIX
|
$ 9.0 | 0.11 % | $ 356 M | ||
|
Outset Medical
OM
|
$ 3.48 | 0.7 % | $ 52.9 K | ||
|
Aethlon Medical
AEMD
|
$ 1.82 | 1.31 % | $ 1.23 M | ||
|
Align Technology
ALGN
|
$ 154.0 | 0.03 % | $ 11.2 B | ||
|
Delcath Systems
DCTH
|
$ 16.1 | 1.1 % | $ 577 M | ||
|
PAVmed
PAVM
|
$ 4.9 | 3.73 % | $ 3.29 M | ||
|
Inogen
INGN
|
$ 5.26 | 0.18 % | $ 140 M | ||
|
InMode Ltd.
INMD
|
$ 14.79 | 0.47 % | $ 956 M | ||
|
OrthoPediatrics Corp.
KIDS
|
$ 21.84 | 1.17 % | $ 512 M | ||
|
Penumbra
PEN
|
$ 320.07 | 0.32 % | $ 12.5 B | ||
|
Insulet Corporation
PODD
|
$ 139.77 | 1.65 % | $ 9.83 B | ||
|
Quanterix Corporation
QTRX
|
$ 2.71 | 0.56 % | $ 116 M | ||
|
AVITA Medical
RCEL
|
$ 10.58 | 2.38 % | $ 295 M | ||
|
Integer Holdings Corporation
ITGR
|
$ 126.39 | 0.8 % | $ 4.39 B | ||
|
Sintx Technologies
SINT
|
$ 1.67 | 2.45 % | $ 4.63 M | ||
|
Smith & Nephew plc
SNN
|
$ 27.84 | 0.16 % | $ 24.1 B | ||
|
Sensus Healthcare
SRTS
|
$ 3.2 | 0.31 % | $ 52.2 M | ||
|
Stryker Corporation
SYK
|
$ 276.24 | 0.68 % | $ 106 B | ||
|
Tactile Systems Technology
TCMD
|
$ 21.54 | 0.09 % | $ 493 M |